Overview

* Replimune ( REPL ) fiscal Q2 net loss widens to $83.1 mln from $53.1 mln last year

* Cash position decreases to $323.6 mln from $483.8 mln as of March 31, 2025

Outlook

* Replimune ( REPL ) expects FDA decision on RP1 BLA by April 2026

* Company plans to fund operations into late 2026

Result Drivers

* R&D EXPENSES - Increase in R&D expenses due to higher costs for RP1 and RP2 studies, including IGNYTE-3

* FDA ACCEPTANCE - FDA accepted BLA resubmission for RP1, potential approval progress

* CLINICAL TRIAL PROGRESS - Positive data from IGNYTE trial for RP1 plus nivolumab in skin cancers

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q2 Net -$83.10

Income mln

Q2 Basic -$0.90

EPS

Q2 Cash $323.60

& mln

Investme

nts

Q2 $84.29

Operatin mln

g

Expenses

Q2 -$84.29

Operatin mln

g Income

Analyst Coverage

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 6 "strong buy" or "buy", 3 "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the biotechnology & medical research peer group is "buy"

* Wall Street's median 12-month price target for Replimune Group Inc ( REPL ) is $12.50, about 31.4% above its November 5 closing price of $8.58

Press Release:

For questions concerning the data in this report, contact [email protected]. For any other questions or feedback, contact .

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)